Screener
Indivior Pharmaceuticals, Inc. INDV Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of long-term debt | — | 29 |
| Operating lease liabilities, current | 9 | 10 |
| Income taxes payable | 26 | 2 |
| Total current liabilities | 779 | 914 |
| Long-term debt, less current portion | 486 | 290 |
| Accrued litigation settlement expenses, noncurrent | 41 | 52 |
| Operating lease liabilities, noncurrent | 14 | 22 |
| Other noncurrent liabilities | 21 | 21 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s total current liabilities?
- Indivior Pharmaceuticals, Inc. (INDV) reported total current liabilities of $779M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s total current liabilities decreased by 22.5% year-over-year, from $1.01B to $779M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s total current liabilities?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s total current liabilities has grown at a -15.5% compound annual growth rate (CAGR), from $1.28B to $914M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Indivior Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude